INGN · CIK 1294133
What Inogen, Inc. told the SEC could break it.
Inogen's disclosures cluster on a concentrated supply chain and reimbursement dependence. It sources some components, subassemblies, and even completed products from single-source or a limited group of suppliers — with three major vendors alone accounting for about 40% of raw-material purchases in 2025 — so losing a supplier could disrupt manufacturing. Within that, semiconductor chips are a pressure point: higher cost premiums on open-market chip purchases for its portable oxygen concentrators helped push 2025 gross margin down to 44.5%. On the revenue side, its rental business leans on Medicare, whose fee-for-service programs were about 61.9% of rental revenue in 2025, so changes to home-oxygen reimbursement rates or policy would directly hit that stream.
4 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Sole-source dependency
- Single-source / limited suppliers for key components and completed productshigh
Inogen sources some components, subassemblies, and completed products from single-source suppliers or a limited group of manufacturers; some components are available only in limited supply, so loss of a supplier could disrupt manufacturing and product sales.
“We obtain some components, subassemblies, and completed products included in our products from single source suppliers or from a limited group of manufacturers or suppliers.”
SEC filing →As of 2026
Commodity & input dependence
- Semiconductor chip cost premiums for portable oxygen concentratorsmedium
Inogen's sales gross margin fell to 44.5% in 2025 partly due to higher cost premiums on open-market purchases of semiconductor chips used in its portable oxygen concentrators, exposing it to chip availability and pricing.
“higher cost premiums associated with open-market purchases of semiconductor chips used in our POCs”
Regulatory & policy
- Medicare reimbursement dependence for rental revenuemedium
Medicare's traditional fee-for-service reimbursement programs accounted for ~61.9% of Inogen's rental revenue in 2025, so changes to Medicare reimbursement rates or policies for home oxygen could reduce that revenue stream.
“Medicare's service reimbursement programs accounted for 61.9 %, 56.3 % and 67.7 % of rental revenue in 2025, 2024 and 2023 , respectively”
SEC filing →As of 2026
Supplier concentration
- Three major vendors supply ~40% of raw material purchasesmedium
Inogen purchases raw materials from a limited number of vendors, concentrated in three major vendors that accounted for 17.9%, 12.1%, and 10.5% of total raw material purchases in 2025, creating dependence on a few suppliers.
“the Company's three major vendors accounted for 17.9 %, 12.1 % and 10.5 %, respectively, of total raw material purchases.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
Foxconn (Hon Hai Precision)
“we produce our Inogen Rove 6 concentrators and perform related repair activities using a contract manufacturer, Foxconn, located in the Czech Republic to improve our ability to efficiently service our European customers.”
Cited →Yuwell (Jiangsu Yuwell Medical Equipment & Supply Co., Ltd.)
“Yuwell (Hong Kong) Holdings Limited has agreed to purchase 2,626,425 shares of the Company's common stock at a price per share of $10.36, for an aggregate purchase price of approximately $27.2 million.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch